Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912462518> ?p ?o ?g. }
- W2912462518 endingPage "374" @default.
- W2912462518 startingPage "374" @default.
- W2912462518 abstract "Prices for newer analogue insulin products have increased. Lower-cost human insulin may be effective for many patients with type 2 diabetes.To evaluate the association between implementation of a health plan-based intervention of switching patients from analogue to human insulin and glycemic control.A retrospective cohort study using population-level interrupted times series analysis of members participating in a Medicare Advantage and prescription drug plan operating in 4 US states. Participants were prescribed insulin between January 1, 2014, and December 31, 2016 (median follow-up, 729 days). The intervention began in February 2015 and was expanded to the entire health plan system by June 2015.Implementation of a health plan program to switch patients from analogue to human insulin.The primary outcome was the change in mean hemoglobin A1c (HbA1c) levels estimated over three 12-month periods: preintervention (baseline) in 2014, intervention in 2015, and postintervention in 2016. Secondary outcomes included rates of serious hypoglycemia or hyperglycemia using ICD-9-CM and ICD-10-CM diagnostic codes.Over 3 years, 14 635 members (mean [SD] age: 72.5 [9.8] years; 51% women; 93% with type 2 diabetes) filled 221 866 insulin prescriptions. The mean HbA1c was 8.46% (95% CI, 8.40%-8.52%) at baseline and decreased at a rate of -0.02% (95% CI, -0.03% to -0.01%; P <.001) per month before the intervention. There was an association between the start of the intervention and an overall HbA1c level increase of 0.14% (95% CI, 0.05%-0.23%; P = .003) and slope change of 0.02% (95% CI, 0.01%-0.03%; P < .001). After the completion of the intervention, there were no significant differences in changes in the level (0.08% [95% CI, -0.01% to 0.17%]) or slope (<0.001% [95% CI, -0.008% to 0.010%]) of mean HbA1c compared with the intervention period (P = .09 and P = 0.81, respectively). For serious hypoglycemic events, there was no significant association between the start of the intervention and a level (2.66/1000 person-years [95% CI, -3.82 to 9.13]; P = .41) or slope change (-0.66/1000 person-years [95% CI, -1.59 to 0.27]; P = .16). The level (1.64/1000 person-years [95% CI, -4.83 to 8.11]; P = .61) and slope (-0.23/1000 person-years [95% CI, -1.17 to 0.70]; P = .61) changes in the postintervention period were not significantly different compared with the intervention period. The baseline rate of serious hyperglycemia was 22.33 per 1000 person-years (95% CI, 12.70-31.97). For the rate of serious hyperglycemic events, there was no significant association between the start of the intervention and a level (4.23/1000 person-years [95% CI, -8.62 to 17.08]; P = .51) or slope (-0.51/1000 person-years [95% CI, -2.37 to 1.34]; P = .58) change.Among Medicare beneficiaries with type 2 diabetes, implementation of a health plan program that involved switching patients from analogue to human insulin was associated with a small increase in population-level HbA1c." @default.
- W2912462518 created "2019-02-21" @default.
- W2912462518 creator A5000713705 @default.
- W2912462518 creator A5002975957 @default.
- W2912462518 creator A5040035033 @default.
- W2912462518 creator A5044536098 @default.
- W2912462518 creator A5051657336 @default.
- W2912462518 creator A5059157113 @default.
- W2912462518 creator A5067102899 @default.
- W2912462518 creator A5068162108 @default.
- W2912462518 creator A5074257304 @default.
- W2912462518 date "2019-01-29" @default.
- W2912462518 modified "2023-10-16" @default.
- W2912462518 title "Implementation of a Health Plan Program for Switching From Analogue to Human Insulin and Glycemic Control Among Medicare Beneficiaries With Type 2 Diabetes" @default.
- W2912462518 cites W1526927233 @default.
- W2912462518 cites W172609984 @default.
- W2912462518 cites W1887292959 @default.
- W2912462518 cites W1916729748 @default.
- W2912462518 cites W1953393606 @default.
- W2912462518 cites W1985992465 @default.
- W2912462518 cites W2018330140 @default.
- W2912462518 cites W2029698668 @default.
- W2912462518 cites W2048981123 @default.
- W2912462518 cites W2064414668 @default.
- W2912462518 cites W2101071243 @default.
- W2912462518 cites W2102127536 @default.
- W2912462518 cites W2123946565 @default.
- W2912462518 cites W2126781806 @default.
- W2912462518 cites W2139912326 @default.
- W2912462518 cites W2154376439 @default.
- W2912462518 cites W2302447233 @default.
- W2912462518 cites W2315065380 @default.
- W2912462518 cites W2337454357 @default.
- W2912462518 cites W2462394222 @default.
- W2912462518 cites W2587084953 @default.
- W2912462518 cites W2616009730 @default.
- W2912462518 cites W2626730270 @default.
- W2912462518 cites W2735325912 @default.
- W2912462518 cites W2780645176 @default.
- W2912462518 cites W2808886614 @default.
- W2912462518 cites W2808944450 @default.
- W2912462518 cites W4230866161 @default.
- W2912462518 cites W4246968586 @default.
- W2912462518 doi "https://doi.org/10.1001/jama.2018.21364" @default.
- W2912462518 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6439763" @default.
- W2912462518 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30694321" @default.
- W2912462518 hasPublicationYear "2019" @default.
- W2912462518 type Work @default.
- W2912462518 sameAs 2912462518 @default.
- W2912462518 citedByCount "29" @default.
- W2912462518 countsByYear W29124625182019 @default.
- W2912462518 countsByYear W29124625182020 @default.
- W2912462518 countsByYear W29124625182021 @default.
- W2912462518 countsByYear W29124625182022 @default.
- W2912462518 countsByYear W29124625182023 @default.
- W2912462518 crossrefType "journal-article" @default.
- W2912462518 hasAuthorship W2912462518A5000713705 @default.
- W2912462518 hasAuthorship W2912462518A5002975957 @default.
- W2912462518 hasAuthorship W2912462518A5040035033 @default.
- W2912462518 hasAuthorship W2912462518A5044536098 @default.
- W2912462518 hasAuthorship W2912462518A5051657336 @default.
- W2912462518 hasAuthorship W2912462518A5059157113 @default.
- W2912462518 hasAuthorship W2912462518A5067102899 @default.
- W2912462518 hasAuthorship W2912462518A5068162108 @default.
- W2912462518 hasAuthorship W2912462518A5074257304 @default.
- W2912462518 hasBestOaLocation W29124625181 @default.
- W2912462518 hasConcept C126322002 @default.
- W2912462518 hasConcept C134018914 @default.
- W2912462518 hasConcept C187212893 @default.
- W2912462518 hasConcept C2426938 @default.
- W2912462518 hasConcept C2777180221 @default.
- W2912462518 hasConcept C2779306644 @default.
- W2912462518 hasConcept C2780473172 @default.
- W2912462518 hasConcept C2780668416 @default.
- W2912462518 hasConcept C2781232474 @default.
- W2912462518 hasConcept C2908647359 @default.
- W2912462518 hasConcept C555293320 @default.
- W2912462518 hasConcept C71924100 @default.
- W2912462518 hasConcept C72563966 @default.
- W2912462518 hasConcept C98274493 @default.
- W2912462518 hasConcept C99454951 @default.
- W2912462518 hasConceptScore W2912462518C126322002 @default.
- W2912462518 hasConceptScore W2912462518C134018914 @default.
- W2912462518 hasConceptScore W2912462518C187212893 @default.
- W2912462518 hasConceptScore W2912462518C2426938 @default.
- W2912462518 hasConceptScore W2912462518C2777180221 @default.
- W2912462518 hasConceptScore W2912462518C2779306644 @default.
- W2912462518 hasConceptScore W2912462518C2780473172 @default.
- W2912462518 hasConceptScore W2912462518C2780668416 @default.
- W2912462518 hasConceptScore W2912462518C2781232474 @default.
- W2912462518 hasConceptScore W2912462518C2908647359 @default.
- W2912462518 hasConceptScore W2912462518C555293320 @default.
- W2912462518 hasConceptScore W2912462518C71924100 @default.
- W2912462518 hasConceptScore W2912462518C72563966 @default.
- W2912462518 hasConceptScore W2912462518C98274493 @default.
- W2912462518 hasConceptScore W2912462518C99454951 @default.
- W2912462518 hasIssue "4" @default.
- W2912462518 hasLocation W29124625181 @default.